Home > Urology > EAU 2021 > Bladder Cancer > Durvalumab ± tremelimumab by cisplatin eligibility in metastatic urothelial carcinoma

Durvalumab ± tremelimumab by cisplatin eligibility in metastatic urothelial carcinoma

Presented By
Prof. Thomas Powles, Barts Cancer Centre, London, UK
Conference
EAU 2021
Trial
Phase 3, DANUBE
The randomised, phase 3 DANUBE trial did not achieve its co-primary endpoints. Therefore, data presented at EAU21 were exploratory. Durvalumab showed activity in the cisplatin-ineligible, PD-L1high population, which is in line with results for other immune checkpoint inhibitors in this population. Tremelimumab appeared to improve the activity of durvalumab when given in combination [1]. Based on single-arm trials, atezolizumab and pembrolizumab are currently licensed in cisplatin-ineligible, PD-L1-positive patients in the first-line setting. Randomised phase 3 trials have not yet shown overall survival (OS) benefit for these immune checkpoint inhibitors over chemotherapy. There is little prospective data on the comparative efficacy of cisplatin and carboplatin in patients with a good performance status, but carboplatin is considered inferior to cisplatin. The DANUBE trial (


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on